Skip to content
Wednesday, November 11, 2026
Summit Slot Plus

{‘She lacks zero qualifications’: the American scientific field prepares for Dr. Høeg's tenure at the Food and Drug Administration.

As the US undertakes historic revisions to its vaccine recommendations, a particular individual has surfaced unexpectedly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning COVID-19 shots throughout the global health crisis and has zeroed in on potential deaths after COVID-19 vaccination in her short position at the FDA.

Planned Overhauls to Pediatric Vaccine Program

Public health authorities were set to announce sweeping revisions to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US out of alignment with a large portion of the global community with no evidence for public health gain. The planned update has been pushed back until the coming year.

In place of the director of the vaccine center, Dr. Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s CDER, the fifth person to run the office this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US in order to be more in line with Denmark, a country with comprehensive healthcare and a population about the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – traditionally the domain of Prasad, head of the FDA’s vaccine center – instead of medication approval.

Doubts Over Qualifications

The appointee has no obvious experience in medication creation, oversight or management, which has been typical for former heads of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for running the CDER, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in managing a large organization. She has no expertise in drug approvals.”

Previous directors of CBER would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she lacks the type of experience that former directors who led CBER have had.”

CDER has an vast workload at the FDA, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and each of these need to be looked after,” Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial administrative element to the role, which supervises in excess of 5,000 personnel. “It’s a enormous management job, if you do it right,” the former official said.

Agency Reaction and Controversial Initiatives

In response to questions about Høeg’s qualifications and whether this assignment indicates more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “inquiries rely on flawed assumptions”.

“Her resume is consistent with the functions of her job,” the official explained, citing the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that apparently troubled her preceding directors. “By what process are these drugs being selected for this fast-track system? Who is making the calls?” Howard asked. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of all drugs, except for immunizations.”

Public Past Work on Vaccines

With immunizations, Dr. Høeg has a more established, if problematic, track record, some experts observe. She authored a research paper using non-validated public submissions to assess the incidence of heart inflammation after Covid immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the new government encompassed changing regulations for new vaccines and discontinuing “optional” vaccines, she stated after the election on a audio program. At the agency, Høeg has reportedly suggested barring young men from obtaining Covid vaccinations.

“She’s an thorough dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the data in a very deceptive, fraudulent way,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of other contrarians, {like|

Written by

Jennifer Martinez

A seasoned casino analyst and gaming enthusiast with over a decade of experience in reviewing online slots and developing winning strategies.

Summit Slot Plus

Type to search articles.